ABBV-8736

Phase 2Small molecule

AbbVie

ABBV-8736 is one of 54 small molecule programs targeting Crohn's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Crohn's DiseaseRecruiting

Adverse EventsActive, not recruiting

Crohn's DiseasePhase 2

Recruiting

Adverse EventsPhase 1

Active, not recruiting

Competition

Competitive Landscape

74 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

Remicade

Johnson & Johnson

Approved

28 2

Humira

Novartis

Approved

22 3

Entyvio

Takeda

Approved

13 4

Omvoh

Eli Lilly

Approved

8 5

Trexall

Jazz Pharmaceuticals

Approved

1 6

Rocaltrol

Mycobutin

Opzelura

Calciferol

Levulan

Sun Pharmaceutical Industries, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

Crohn's Disease

NCT06548542

Clinical

Trials by Indication[1]

Adverse Events1 trial

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT07141199·24 enrolled

Crohn's Disease1 trial

A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT06548542·540 enrolled

Unspecified1 trial

A Phase 1 Pharmacokinetic Study in Healthy Adult Volunteers to Evaluate the Bioavailability of ABBV-8736 Following Subcutaneous Administration Relative to Intravenous Administration

Completed· AbbVie logo

AbbVie·Phase 1·NCT07413133·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ABBV-8736. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABBV-8736 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABBV-8736. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AbbVie

ABBV-8736

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Adverse Events1 trial

Crohn's Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News